Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Items 401–500 of 548
Methicillin-resistant Staphylococcus aureus
Parsons, J. B., Westgeest, A. C., Conlon, B. P., Harbarth, S., Howden, B. P., Kim, Y. S., King, H. A., Lambregts, M. M. C., Miller, L. G., Patel, R., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00729-3 · Cited by 3
“Although daptomycin is not recommended for MRSA pneumonia because it is inactivated by pulmonary surfactant 278 , no differences in treatment success were observed among patients with septic pulmonary emboli randomized to receive daptomycin in the registrational phase III trial 234 .”
Barman, T. K., Kumar, M., Chaira, T., Singhal, S., Mathur, T., Kalia, V., Gangadharan, R., Rao, M., Pandya, M., Bhateja, P., et al. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0207 · Cited by 3
Nussbaumer-Pröll, A. K., Matzneller, P., Eberl, S., & Zeitlinger, M. A. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04799-7 · Cited by 3
“…pulmonary mycoses has prompted exploration, given its critical role in preventing alveolar collapse and its potential as a vehicle for enhanced antibiotic drug delivery, as seen in previous research on daptomycin facing commercial challenges due to inhibited activity in its presence [5, 7, 8].”
BackgroundMartí, V. H., Sánchez, E. R., Salavert, M., Bosó, V., & Andrés, J. L. P. (2007) · PubMed · Cited by 7
Saravu, K., Mukhopadhyay, C., Satyanarayanan, V., Pai, A., Komaranchath, A. S., Munim, F. C., Shastry, B. A., & Devasia, T. (2012) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2012.657233 · Cited by 3
Community-Associated Methicillin-Resistant Staphylococcus aureus
Miller, L. G., & Eells, S. J. (2014) · ASM Press eBooks · doi:10.1128/9781555815592.ch12 · Cited by 3
Antibiotic Consideration in Transplant Recipients
Altshuler, J., Aitken, S. L., Maslow, M. J., Papadopoulos, J., & Safdar, A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_50 · Cited by 3
Halim, S. V., & Setiawan, E. (2020) · Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) · doi:10.22487/j24428744.2020.v6.i1.15015 · Cited by 3
Rauwolf, K. K., Hörtnagl, C., Lass‐Flörl, C., & Groll, A. H. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab422 · Cited by 3
Acute Eosinophilic Pneumonia Secondary to Daptomycin
Somoza-Cano, F. J., MAKADIA, A., Cruz-Peralta, M., Zakarna, L., Demyda, E., Armashi, A. R. A., Patell, K., & Altaqi, B. (2021) · Cureus · doi:10.7759/cureus.19403 · Cited by 3
“Then, alveolar macrophages release a potent eosinophil chemoattractant, eotaxin, leading to further aggregation of these cells within the lung [3-5].”
BackgroundThe Chiral Target of Daptomycin Is the 2R,2′S Stereoisomer of Phosphatidylglycerol
Moreira, R., & Taylor, S. D. (2021) · Angewandte Chemie · doi:10.1002/ange.202114858 · Cited by 3
Optimizing Antibiotic Use in the Intensive Care Unit
Ulldemolins, M., Roberts, J. A., & Lipman, J. (2010) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3181e47953 · Cited by 3
“On the other hand, despite exhibiting good lung penetration profiles, daptomycin has not been approved for the treatment of pneumonia because the pulmonary surfactant present in the alveoli inactivates the daptomycin molecule leading to potential therapeutic failure.(35) Other antibiotics such as levofloxacin have als…”
BackgroundDaptomycin for highly resistant Enterococcus faecium infection
Rosin, C., Bernsmeier, C., Entenza, J. M., Moreillon, P., Frei, R., Weisser, M., & Flückiger, U. M. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13603 · Cited by 3
Current use of daptomycin in cardiac surgery and postoperative intensive care
Kanzler, I., Weis, F. C., & Beiras-Fernández, A. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.3 · Cited by 3
Ohata, K., Kitagawa, J., Niwa, T., Takahashi‐Yamauchi, T., Harada, S., Matsumoto, T., Nakamura, N., Nakamura, H., Kanemura, N., Shimizu, M., et al. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13215 · Cited by 3
“Age (y), median (range) 53 (23-72) 49 (17-66) .”
Yenişehirli, G., Yenişehirli, A., Bulut, Y., & Bulut, N. (2015) · ANKEM Dergisi · doi:10.5222/ankem.2015.021 · Cited by 3
Severe Staphylococcal Infections in Children
Gonzalez, B. E., & Kaplan, S. L. (2008) · Pediatric Annals · doi:10.3928/00904481-20081001-07 · Cited by 4
Aguilar, L., Barberán, J., Prieto, J. G., & Giménez, M.-J. (2008) · Revista española de quimioterapia. Suplemento · Cited by 3
Community acquired methicillin resistant Staphylococcus aureus: A Wisconsin perspective.
Proctor, R. A. (2006) · PubMed · Cited by 4
Kang, M. W., & Ahn, S. Y. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.08.012 · Cited by 2
Abdelsamie, A. S., Konstantinović, J., Kany, A. M., Schütz, C., Kolling, D., Speicher, S., Klein, A., Shafiei, R., Bouté, M., Mundry, K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02788 · Cited by 2
“31 Hence, we assessed potential effects of surfactant on the in vitro activity of selected LasB inhibitors by adding 1% porcine lung surfactant to the FRET assay.”
Davison, S., Bryce, A. N., Campbell, D., Baird, R., Ewin, T., Ullah, S., Janson, S., & Tsai, D. (2026) · Internal Medicine Journal · doi:10.1111/imj.70472 · Cited by 2
Tebano, G., Convertino, C., Raumer, L., Sgarzani, R., Melandri, D., & Cristini, F. (2026) · European Burn Journal · doi:10.3390/ebj7020035 · Cited by 2
Kobuchi, S., Kita, Y., Hiramatsu, Y., Sasaki, K., Uno, T., Ιtο, Y., & Sakaeda, T. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.045 · Cited by 2
Castrodad‐Rodríguez, C. A., Orner, E. P., & Szymczak, W. A. (2021) · Academic Pathology · doi:10.1177/23742895211015343 · Cited by 2
“The decrease in its efficacy in the lungs is explained by daptomycin being inactivated by its interaction with pulmonary surfactants which results in the inhibition of its antibacterial activity.(38,39) For our patient, empiric therapy should include vancomycin instead of daptomycin.”
BackgroundPramesti, C. A. A., Khikmah, N., & Sulistyani, N. (2022) · Jurnal Biologi Udayana · doi:10.24843/jbiounud.2022.v26.i01.p12 · Cited by 2
“Antibiotik tersebut masih tergolong mahal (Kali, 2015) dan daptomycin yang tidak efektif untuk kasus infeksi MRSA di paru-paru (Silverman et al., 2005; Sauermann et al., 2008).”
BackgroundCommunity-Acquired Methicillin-Resistant Staphylococcus aureus Pneumonia
Mahapatra, S., Reddy, S., Duggal, S., Algheriani, H., Botros, M., Vulisha, A. K., & Rao, S. (2024) · Cureus · doi:10.7759/cureus.72166 · Cited by 2
Management of MDR/XDR severe infections in the critically ill
Mezzadri, L., Chang, Y.-T., & Paterson, D. L. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001307 · Cited by 2
New Antibiotics for Gram-Positive Infections
Bradley, J. S. (2006) · Springer eBooks · doi:10.1007/0-387-33026-7_13 · Cited by 2
“Studies in adults with staphylococcal pneumonia suggested clinical response rates which were not equivalent to vancomycin, raising the possibility that the distribution of unbound antibiotic in bronchial-alveolar lining fl uid and lung parenchyma was insuffi cient to achieve the required antibiotic exposure in those t…”
BackgroundCommunity-associated Staphylococcus aureus infections: pneumonia
Karvouniaris, M., Makris, D. A., & Zakynthinos, E. G. (2010) · Microbiology Research · doi:10.4081/mr.2010.e4 · Cited by 5
“Despite covering MRSA, daptomycin is inhibited by surfactant in vitro and is therefore not suitable for treating pneumonia.(59) The role of tigecycline, ceftobiprole (cephalosporin with anti-MRSA activity), novel glycopeptides (dalbavancin, telavancin, oritavancin), and iclaprim has not been defined for the treatment…”
BackgroundRHODOSTOMIN, A SNAKE VENOM DISINTEGRIN, SERVED AS A MOLECULAR TOOL TO DISSECT THE INTEGRIN FUNCTION
Chang, H., & Lo, S. J. (2007) · Toxin Reviews · doi:10.1080/15569540701209823 · Cited by 2
“In previous studies, however, the hemorrhaging caused by anthrax lethal toxin was not considered as a mechanism that leads to death (Cui et al., 2005; Jones et al., 2005; Silverman et al., 2005; Artenstein et al., 2004).”
BackgroundHermsen, E. D., Shull, S. S., Mitropoulos, I. F., Puumala, S. E., & Rupp, M. E. (2009) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318184d74e · Cited by 2
“Although linezolid is FDA-approved for the treatment of pneumonia, daptomycin is not approved for this indication because of data suggesting an interaction between daptomycin and surfactant, leading to drug inactivity.(15) Daptomycin and linezolid offer several advantages over vancomycin and oxacillin.”
BackgroundUse of daptomycin for treatment ofStaphylococcus aureusinfections
Eisenstein, B. I. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.11.1523 · Cited by 3
“The clinical efficacy of daptomycin was 79 versus 87% for ceftriaxone [78] .”
BackgroundInfluentialAntibiotika zur Behandlung von Infektionen durch Methicillin-resistente Staphylococcus aureus (MRSA)
Stahlmann, R. (2014) · Pneumologie · doi:10.1055/s-0034-1377747 · Cited by 2
Baltz, R. H. (2009) · Royal Society of Chemistry eBooks · doi:10.1039/9781847559890-00395 · Cited by 2
Molina, F., Agudelo, C. A., Fonseca-Ruiz, N. J., Hidrón, A., Jiménez, C. A., Ochoa, Á., Restrepo, C. A. A., Trompa, I. M., & Roncancio, G. E. (2015) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2015.11.001 · Cited by 2
Animal Models to Evaluate Anti-infective Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_3 · Cited by 2
Huang, D. B., Duncan, L. R., Flamm, R. K., Dryden, M., Corey, G. R., Wilcox, M. H., Torres, A., & File, T. M. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.09.011 · Cited by 2
“This inhibitory MIC effect of surfactant on daptomycin activity has been reported to be mediated by binding of surfactant components to specific structures present on antibiotics, such as the the lipophilic side-chain of daptomycin (Silverman et al., 2005).”
InfluentialNogid, B., Lacy, M. K., Jacobs, M., BRUSS, J. B., & Dwyer, J. P. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2165 · Cited by 2
“9 Daptomycin, an alternative antibiotic used to treat MRSA, is not an effective treatment for pneumonia, as it is inhibited by pulmonary surfactant, a major component of epithelial lining fluid (ELF).(10) The newer, long-acting lipoglycopeptides, oritavancin and dalbavancin, are currently untested for the treatment of…”
BackgroundCai, D. (2020) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2020.04.011 · Cited by 2
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Eckhardt, L. G. J., Kelley, J. L., & Maes, D. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07852-y · Cited by 2
“The activity of daptomycin is dependent on free calcium to insert and disrupt the integrity of the gram positive plasma membranes leading to cell death [3, 8].”
BackgroundIntroduction to the Symposium on Antimicrobial Therapy
Temesgen, Z. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0002 · Cited by 4
Gatti, M., & Pea, F. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae017 · Cited by 2
Machhua, P., Unnithan, V. G., Liu, Y., Jiang, Y., Zhang, L., & Guo, Z. (2024) · eLife · doi:10.7554/elife.93267.2 · Cited by 2
Daptomycin: Mechanism of Action and Bacterial Resistance
Zhang, T. (2015) · UWSpace (University of Waterloo) · Cited by 2
Selig, D. J., Caridha, D., Evans, M. O., Kress, A. T., Lanteri, C. A., Ressner, R. A., & DeLuca, J. P. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010111 · Cited by 1
“However, some antibiotics may not penetrate the lung as effectively as others [31] or may be inactivated in lung tissue, such as daptomycin [32].”
BackgroundDiagnosis and Management of Daptomycin-Induced Acute Eosinophilic Pneumonia: A Case Report
Elbarbry, F., Farthing, K., & Arguello, S. (2024) · INNOVATIONS in pharmacy · doi:10.24926/iip.v15i2.6200 · Cited by 1
Cañas, M.-A., de la Mària, C. G., García‐González, J., Jiménez, M. P., Marco, F., Sarasa, M., Meneses, M. H., Quintana, E., Falces, C., Tolosana, J. M., et al. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf149 · Cited by 1
Real-world daptomycin use with a focus on muscle toxicity: A multicentric retrospective study
Airaud, C., Demay, E., Meireles, V. D., Paz, D. L., Tattevin, P., Lazaro, P., Lahouati, M., & Bacle, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107721 · Cited by 1
Goodyear, J., & Taylor, S. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00819 · Cited by 1
Tong, X., Li, J., Tan, Y., Mao, J., Chen, P., Yin, Z., Wang, M., Li, C., Liu, G., Yao, Y., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c03697 · Cited by 1
Lin, L. Y. C., Chuang, Y., Yang, J.-L., Lin, C., Huang, S., Wang, J.-T., Chen, Y.-C., & Chang, S. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01369-6 · Cited by 1
“…that the markedly elevated incidence may reflect a threshold phe‑ nomenon, whereby supratherapeutic exposure above a critical concentration, rather than incre‑ mental dose increases, promotes drug accumu‑ lation near the alveolar surface, triggering epi‑ thelial injury and inflammation [37, 38].”
Kaushik, A., Fomicheva, J., Zellmer, K. A., Thieman, C., & Gupta, S. (2026) · Medicines · doi:10.3390/medicines13020018 · Cited by 1
“Daptomycin is rapidly inactivated by pulmonary surfactant, and surfactant molecules physically trap the antibiotic, preventing it from reaching and disrupting the bacterial cell membranes in the alveoli [62].”
Maximizing positive outcomes for patients with staphylococcal infections
Stahl, J. ‐. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03056.x · Cited by 1
“For example, daptomycin interacts with and is inhibited by pulmonary surfactant, which renders it ineffective for simple bronchoalveolar pneumonia [40].”
BackgroundToplumdan Kazanılmış Metisiline Dirençli Staphylococcus aureus Enfeksiyonlarının Tedavisi
Kaya, S. (2008) · Turkiye Klinikleri Tip Bilimleri Dergisi · Cited by 1
Mise à jour du traitement des infections à Staphylococcus aureus résistant à la méthicilline
Tremblay, C. (2008) · Pharmactuel · Cited by 1
Antibiotic Use in Home Health: A Primer
Bossaer, J. B., & Lewis, P. O. (2011) · Home Health Care Management & Practice · doi:10.1177/1084822311422561 · Cited by 1
“Daptomycin’s inferior activity in pneumonia is reportedly caused by inactivation of the drug in pulmonary surfactant.(18) Daptomycin is a safe drug with a wider therapeutic spectrum than aminoglycoside or vancomycin.”
BackgroundInfección y pie diabético. ¿Existen nuevas posibilidades terapéuticas?
Zaragoza‐Crespo, R., & Blanes-Mompó, J. I. (2006) · Angiología · doi:10.1016/s0003-3170(06)74993-8 · Cited by 1
Nakano, T., Miyazaki, M., Togawa, A., Takata, T., Mishima, K., Iwasaki, K., & Futagami, K. (2014) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.40.147 · Cited by 2
Drug Discovery for Lower Respiratory Tract Infections
Craft, J. C. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733496-00366 · Cited by 1
Li, T., Ying, Q., Li, D., Liu, F., & Guoguang, X. (2018) · Burns Open · doi:10.1016/j.burnso.2018.02.002 · Cited by 1
Self-citationAntibiotic-Resistant Pathogens in Ear, Nose, and Throat Infections
Brook, I. (2018) · Springer eBooks · doi:10.1007/978-3-319-74835-1_2 · Cited by 1
Responsible antibiotic therapy simplified
Shah, A. K., & Shah, A. A. (2020) · Karnataka Pediatric Journal · doi:10.25259/kpj_5_2020 · Cited by 1
Bergin, S. P., Calvert, S. B., Farley, J. J., Sun, J., Chiswell, K., Dieperink, W., Kluytmans, J. A. J. W., Delgado, J. C. L., León‐López, R., Zervos, M., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac231 · Cited by 1
SASCM guideline for daptomycin use in South Africa – 2017 update
Lowman, W., Coetzee, J., & Perovic, O. (2017) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v32i2.58 · Cited by 1
Baltz, R. H. (2013) · Springer eBooks · doi:10.1007/978-3-642-39968-8_6 · Cited by 1
Clinical Trials and Regulatory Issues of Natural Polymers Employed in Respiratory Disease
Hussian, T., Tripathy, S., Dua, K., & Dureja, H. (2023) · Springer eBooks · doi:10.1007/978-981-19-7656-8_22 · Cited by 2
An Unexpected Turn of Events in a Patient With Mitral Valve Endocarditis
Arcalas, C., Artola, R., Hanna, M. E., Li, H., Levy, S., & Kalyatanda, G. (2023) · Cureus · doi:10.7759/cureus.42121 · Cited by 1
“Although the exact mechanism of DEP is not known, it is thought to be related to the drug molecules binding to pulmonary surfactant and causing epithelial cell injury [4,5].”
BackgroundLi, C. N., Patel, S. J., & Collins, C. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03616-4 · Cited by 1
“…[13], understanding the pharmacokinetics and pharmacodynamics of antimicrobials and the presence of body site restrictions for specific antibiotics [14, 15], and the implementation of antimicrobial stewardship principles to protect both the individual patient and the general population [16].”
Lai, H., Woolner, V. H., Little, R. F., Woolly, E. F., Keyzers, R. A., & Owen, J. G. (2024) · Angewandte Chemie · doi:10.1002/ange.202410286 · Cited by 1
Daptomycin-induced pulmonary eosinophilia: early identification of antibiotic side effects
Jaffe, T., Lukes, M., McCraw, C. D., Huang, J., Bode, A., & Gerstein, W. H. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-265819 · Cited by 1
Dabul, A. N. G. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2014.tde-13032014-085110 · Cited by 2
Staphylococcus aureus and healthcare-associated infections
Ekkelenkamp, M. B. (2006) · Utrecht University Repository (Utrecht University) · Cited by 1
Tribulations of trials for antibacterial drugs: interview with Brad Spellberg
Spellberg, B. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.79 · Cited by 1
Guidance for Antibiotic Selection: Tissue Distribution and Target Site Concentration
Matson, K. L., & Fallon, R. M. (2009) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e3181a65376 · Cited by 1
“Further animal studies observed that the lack of efficacy for CAP treatment was due to the antibiotic’s interaction with pulmonary surfactant.(66) Daptomycin’s mechanism of action allows for insertion of the antibiotic into the surfactant layer, thus binding it to the lung tissue and inhibiting its activity.”
BackgroundSevere community-acquired pneumonia in adults: current antimicrobial chemotherapy
Niven, D. J., & Laupland, K. B. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.7.1.69 · Cited by 1
Neumonía nosocomial por grampositivos
Lisboa, T. C., & Rello, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1157/13123566 · Cited by 1
Structure-Activity Relationship Studies on Daptomycin
Barnawi, G. (2018) · UWSpace (University of Waterloo) · Cited by 1
Do Not Forget Daptomycin as a Cause of Eosinophilic Pneumonia!
John, T. M., & Kontoyiannis, D. P. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.10.086 · Cited by 1
Maschmeyer, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_10 · Cited by 1
Pulmonary antimicrobial photodynamic therapy and the role of the lung surfactant
Kassab, G. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2022.tde-18082022-093617 · Cited by 6
Machhua, P., Unnithan, V. G., Liu, Y., Jiang, Y., Zhang, L., & Guo, Z. (2024) · eLife · doi:10.7554/elife.93267.1 · Cited by 1
Mode of Action of Daptomycin, a Lipopeptide Antibiotic
Muraih, J. K. (2013) · UWSpace (University of Waterloo) · Cited by 3
Pathogenomics: Identification of Novel Drug Targets and Vaccine Candidates in Bacteria
Ohlsen, K., Eckart, M., Dobrindt, U., Bruhn, H. D., & Hacker, J. H. (2009) · Wiley eBooks · doi:10.1002/9783527626816.ch20
MacDougall, C., Guglielmo, B. J., & Wiener-Kronish, J. P. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781933.060
The Membrane as a Novel Target Site for Antibiotics to Kill Persisting Bacterial Pathogens
Wu, X., & Hurdle, J. G. (2013) · Antibiotics · doi:10.1002/9783527659685.ch8
Antibiotics in Severe Sepsis: Which Combinations Work?
Welte, T. (2009) · Springer eBooks · doi:10.1007/978-3-642-00479-7_11
“In animal experiments, daptomycin appeared to be unsuitable for the treatment of pneumonia due to the inhibition of protein binding by surfactants [29].”
BackgroundAntibiotics for bacteraemia due to Staphylococcus aureus
Karanth, V. K., Karanth, S. K., & Karanth, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011465.pub2
Daptomicina en el contexto de la resistencia a los antimicrobianos en bacterias grampositivas
Candel, F. J. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(12)70066-6 · Cited by 2
Therapeutic Options for Resistant Gram Positives
Menon, V., & van Hal, S. J. (2014) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-014-0028-y
Fritsche, G., & Weiss, G. (2008) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-008-0057-7
“Daptomycin should not be used for bronchopulmonary infections, since it is deactivated by pulmonary surfactant [ 23 ].”
BackgroundNeue Antibiotika zur Therapie von Atemwegsinfektionen
Kruse, M., & Stahlmann, R. (2006) · Pneumologie · doi:10.1055/s-2006-932185
Daptomycin zur Behandlung grampositiver Infektionen nach herzchirurgischen Eingriffen
Luchting, B., Weis, F. C., Heyn, J., & Beiras-Fernández, A. (2012) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-012-0163-5 · Cited by 1
“Of the remaining patients, those in whom the respiratory tract was designated as the primary focus of infection deserve mention because daptomycin is expressly not recommended for treatment of pulmonary infections [64, 65].”
BackgroundSafety and Efficacy of Daptomycin in the Treatment of Gram-Positive Pathogens
Kelesidis, T. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6122 · Cited by 1
Place de la daptomycine dans les infections ostéoarticulaires
Carsenti-Dellamonica, H. (2010) · Antibiotiques · doi:10.1016/j.antib.2010.05.001
Transmission dynamics and resistance in staphylococci
Hetem, D. J. (2015) · Utrecht University Repository (Utrecht University)
Nathwani, D., & Urquhart, L. (2010) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e3181f9e0a2
“Daptomycin, which has good evidence in the treatment of skin and soft-tissue infections, cannot be used as it is inactivated by lung surfactant.(64)”
BackgroundLane, J. W., Tang, J., Taggard, D. A., & Byun, R. (2011) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e318209948b
“An animal model demonstrates poor activity in bronchial-alveolar pneumonia but retained activity in hematogenous pneumonia.(10) Clinical trials have proven that daptomycin is inferior to ceftriaxone when used in the treatment of community-acquired pneumonia.”
BackgroundFukunaga, S., Ishida, C., Nakaoka, A., & Ito, T. (2014) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.47.563
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.